← Leaderboards
Gary E Gibson
Winifred Masterson Burke Med Res Inst
$20,348,069
Attributed
$42,971,373
Total exposure
11
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $11M · FY2005–25$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$71,408,306 · 12
By mechanism
R01$38,119,931 · 6
P01$33,248,375 · 5
R13$40,000 · 1
Top collaborators
- Barry D Jordan4 shared
- Howard Feldman3 shared
- Jose A Luchsinger3 shared
- Sarah Ann Flowers2 shared
- Pasquale Fonzetti2 shared
- Sheng Zhang2 shared
- M Flint Beal1 shared
- Rajiv R Ratan1 shared
Most similar at Winifred Masterson Burke Med Res Inst
Same institution · by research overlap
- Abraham M Brown$1,863,995
- John P Blass$181,206
- Arthur Joseph Cooper$2,151,731
- Barry D Jordan$582,450
- Caitlin Elizabeth Hill$2,039,243
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposBrainMitochondriaOxidative StressNeuronsNeurofibrillary TanglesResponseLinkS DiseasePathologyAutopsyMetabolismGlucose MetabolismFunctional DisorderGlucoseLeadCellsSiteCognitionMetabolicAge Related NeurodegenerationEnzyme ActivityNerve DegenerationNeural Degeneration
Grant awards (64)
Phase II randomized controlled trial of benfotiamine in early Alzheimer's Disease$9,592,233
R01 · FY2025 · AG · contact PI
Mechanistic links between the benefits of pharmacologically high thiamine (vitamin B1) in Alzheimer's disease to Advanced Glycation Endproducts (AGE)$1,213,766
R01 · FY2025 · AG · contact PI
Mechanistic links between the benefits of pharmacologically high thiamine (vitamin B1) in Alzheimer's disease to Advanced Glycation Endproducts (AGE)$1,018,953
R01 · FY2024 · AG · contact PI
Phase II randomized controlled trial of benfotiamine in early Alzheimer's Disease$11,038,947
R01 · FY2023 · AG · contact PI
Phase II randomized controlled trial of benfotiamine in early Alzheimer's Disease$9,664,204
R01 · FY2022 · AG · contact PI
Mitochondrial and Metabolic Dysfunction in Age-related Neurodegeneration$2,420,583
P01 · FY2020 · AG · contact PI
The tricarboxylic acid (TCA) cycle in neurodegeneration$590,806
P01 · FY2020 · AG · contact PI
Administrative Core$240,029
P01 · FY2020 · AG · contact PI
Mitochondrial and Metabolic Dysfunction in Age-related Neurodegeneration$2,420,583
P01 · FY2019 · AG · contact PI
The tricarboxylic acid (TCA) cycle in neurodegeneration$590,806
P01 · FY2019 · AG · contact PI
Administrative Core$240,029
P01 · FY2019 · AG · contact PI
Mitochondrial and Metabolic Dysfunction in Age-related Neurodegeneration$2,420,583
P01 · FY2018 · AG · contact PI
The tricarboxylic acid (TCA) cycle in neurodegeneration$590,806
P01 · FY2018 · AG · contact PI
Benfotiamine in Alzheimer's Disease: A pilot study$328,785
R01 · FY2018 · AG · contact PI
Administrative Core$240,029
P01 · FY2018 · AG · contact PI
Mitochondrial and Metabolic Dysfunction in Age-related Neurodegeneration$2,420,583
P01 · FY2017 · AG · contact PI
The tricarboxylic acid (TCA) cycle in neurodegeneration$590,804
P01 · FY2017 · AG · contact PI
Benfotiamine in Alzheimer's Disease: A pilot study$328,785
R01 · FY2017 · AG · contact PI
Administrative Core$240,031
P01 · FY2017 · AG · contact PI
Mitochondrial and Metabolic Dysfunction in Age-related Neurodegeneration$2,437,958
P01 · FY2016 · AG · contact PI
The tricarboxylic acid (TCA) cycle in neurodegeneration$592,440
P01 · FY2016 · AG · contact PI
Benfotiamine in Alzheimer's Disease: A pilot study$328,785
R01 · FY2016 · AG · contact PI
Administrative Core$240,261
P01 · FY2016 · AG · contact PI
Benfotiamine in Alzheimer's Disease: A pilot study$188,408
R01 · FY2016 · AG · contact PI
Benfotiamine in Alzheimer's Disease: A pilot study$318,922
R01 · FY2015 · AG · contact PI
Mitochondrial Dysfunction in Neurodegeneration of Aging$1,626,785
P01 · FY2014 · AG · contact PI
Benfotiamine in Alzheimer's Disease: A pilot study$328,785
R01 · FY2014 · AG · contact PI
Mitochondrial Dysfunction in Neurodegeneration of Aging$1,537,309
P01 · FY2013 · AG · contact PI
Mitochondrial Dysfunction in Neurodegeneration of Aging$1,626,788
P01 · FY2012 · AG · contact PI
Mitochondrial Dysfunction in Neurodegeneration of Aging$1,626,781
P01 · FY2011 · AG · contact PI
Mitochondrial Dysfunction in Neurodegeneration of Aging$1,636,811
P01 · FY2010 · AG · contact PI
MITOCHONDRIAL DYSFUNCTION IN NEUROGEGENERATION OF AGING$1,399,439
P01 · FY2009 · AG · contact PI
MITOCHONDRIAL DYSFUNCTION IN NEUROGEGENERATION OF AGING$7,623
P01 · FY2009 · AG · contact PI
MITOCHONDRIAL DYSFUNCTION IN NEUROGEGENERATION OF AGING$1,360,888
P01 · FY2008 · AG · contact PI
MITOCHONDRIAL DYSFUNCTION IN NEUROGEGENERATION OF AGING$1,350,406
P01 · FY2007 · AG · contact PI
Age/Nutrition/Genes in Models of Psychiatric Disorders$283,885
R01 · FY2007 · AG · contact PI
Mitochondria and Oxidative Stress in Neurodegenerative Disorders$40,000
R13 · FY2007 · AG · contact PI
MITOCHONDRIAL DYSFUNCTION IN NEUROGEGENERATION OF AGING$1,395,983
P01 · FY2006 · AG · contact PI
Age/Nutrition/Genes in Models of Psychiatric Disorders$292,364
R01 · FY2006 · AG · contact PI
MITOCHONDRIAL DYSFUNCTION IN NEUROGEGENERATION OF AGING$1,430,806
P01 · FY2005 · AG
Age/Nutrition/Genes in Models of Psychiatric Disorders$299,400
R01 · FY2005 · AG
a-KETOGLUTARATE DEHYDROGENASE IN NEURODEGENERATION$196,004
P01 · FY2005 · AG
ADMINISTRATIVE CORE$96,983
P01 · FY2005 · AG
Age/Nutrition/Genes in Models of Psychiatric Disorders$299,400
R01 · FY2004 · AG
Mitochondiral enzymes/oxidative stress in Alzheimer's$190,125
R01 · FY2004 · AG
Age/Nutrition/Genes in Models of Psychiatric Disorders$299,400
R01 · FY2003 · AG
SIGNAL TRANSDUCTION SYSTEMS IN ALZHEIMERS DISEASE$266,175
R01 · FY2003 · AG
Mitochondiral enzymes/oxidative stress in Alzheimer's$190,125
R01 · FY2003 · AG
MITOCHONDRIAL DYSFUNCTION IN NEURODENEGENERATION/AGING$99,874
P01 · FY2003 · AG
MITOCHONDRIAL DYSFUNCTION IN NEURODENEGENERATION/AGING$57,751
P01 · FY2003 · AG
MITOCHONDRIAL DYSFUNCTION IN NEURODENEGENERATION/AGING$1,159,399
P01 · FY2002 · AG
SIGNAL TRANSDUCTION SYSTEMS IN ALZHEIMERS DISEASE$266,175
R01 · FY2002 · AG
Mitochondiral enzymes/oxidative stress in Alzheimer's$190,125
R01 · FY2002 · AG
Core--Tissue Culture Core$0
P01 · FY2002 · AG
Alpha-ketoglutarate Dehydrogenase in Neurodegeneration$0
P01 · FY2002 · AG
SIGNAL TRANSDUCTION SYSTEMS IN ALZHEIMERS DISEASE$266,175
R01 · FY2001 · AG
Mitochondiral enzymes/oxidative stress in Alzheimer's$190,125
R01 · FY2001 · AG
Core--Tissue Culture Core$0
P01 · FY2001 · AG
Alpha-ketoglutarate Dehydrogenase in Neurodegeneration$0
P01 · FY2001 · AG
AGE/NUTRITION/GENES IN MODELS OF PSYCHIATIRC DISORDERS$279,584
R01 · FY2000 · AG
SIGNAL TRANSDUCTION SYSTEMS IN ALZHEIMERS DISEASE$266,175
R01 · FY2000 · AG
Mitochondiral enzymes/oxidative stress in Alzheimer's$190,125
R01 · FY2000 · AG
Core--Tissue Culture Core$181,208
P01 · FY2000 · AG
Alpha-ketoglutarate Dehydrogenase in Neurodegeneration$181,206
P01 · FY2000 · AG